Novo Nordisk AS (XTER:NOV)
€ 99.51 -3.09 (-3.01%) Market Cap: 442.81 Bil Enterprise Value: 440.41 Bil PE Ratio: 35.07 PB Ratio: 27.45 GF Score: 91/100

Novo Nordisk A/S at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 02:10PM GMT
Release Date Price: €28.59 (-1.70%)
Richard Vosser
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning, good afternoon. Welcome to the 39th JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst at JPMorgan. And it gives me great pleasure to welcome Lars Fruergaard Jørgensen, CEO of Novo Nordisk to the conference. In contrast to some other sessions at this conference, I get to quiz Lars about everything to do with Novo in the next 40 minutes. So I'm really looking forward to that, and I hope you are, too.

And with that, welcome, Lars, and I'll dive into some Q&A.

Lars Fruergaard Jorgensen;S;President
Novo Nordisk A;CEO & Member of Management Board

/- -

Thank you for having me.

Questions & Answers

Richard Vosser
JPMorgan Chase & Co, Research Division - Senior Analyst

Excellent. It's our pleasure. And normally, we'd be sitting opposite to each other in San Francisco. But of course, things are still, as we all know, less than normal. So

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot